Evidence - Neuroendocrine Cancer UK

NICE approves Avelumab

by Leanne Talbot | Apr 21, 2021

21st APRIL NICE APPROVES AVELUMAB Neuroendocrine Cancer UK is delighted to share with you NICE’s approval of Avelumab as a first line therapy option in metastatic MCC. Avelumab is now recommended as an option for treating metastatic Merkel cell carcinoma in adults...

NICE launches their 2021-2026 strategy

by Leanne Talbot | Apr 20, 2021

Yesterday, Monday April 19th, NICE launched their 2021-2026 strategy ” a vision for the future”. According to NICE – Public and patients will see: – An interactive guideline structure that facilitates links to the underpinning evidence and...

The Role of Patient Support Groups in Neuroendocrine Neoplasms Publication

by Leanne Talbot | Mar 24, 2021

NCUK is excited to announce that its review article “The Role of Patient Support Groups in Neuroendocrine Neoplasms”, co-authored by Catherine Bouvier and Teodora Kolarova (International Neuroendocrine Cancer Alliance), has been accepted for publication in Current...

NICE approves Avelumab

NICE launches their 2021-2026 strategy

The Role of Patient Support Groups in Neuroendocrine Neoplasms Publication

About Us

Subscribe

Contact

Helpline: 0800 434 6476

Office: 01926 883 487

Holly House, 74 Upper Holly Walk, Leamington Spa CV32 4JL

Email us